Switch theme
Sign up to access all valuation multiples
Tecan Group AG sells automated laboratory instruments and solutions for the diagnostics and life sciences research markets. The firm operates in two segments; The Life Sciences Business (end-customer business) segment supplies end users with automated workflow solutions directly. These solutions include laboratory instruments, software packages, application know-how, services, consumables, and spare parts, The partnering Business (OEM business) segment develops and manufactures OEM instruments and components that are distributed by partner companies under their names. A majority proportion of Tecan's revenue is generated in the Americas and Europe.
1980
3.9K+
LTM Revenue $1.1B
LTM EBITDA $193M
$2.4B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Tecan Group has a last 12-month revenue (LTM) of $1.1B and a last 12-month EBITDA of $193M.
In the most recent fiscal year, Tecan Group achieved revenue of $1.1B and an EBITDA of $178M.
Tecan Group expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Tecan Group valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.1B | XXX | $1.1B | XXX | XXX | XXX |
| Gross Profit | $387M | XXX | $385M | XXX | XXX | XXX |
| Gross Margin | 35% | XXX | 34% | XXX | XXX | XXX |
| EBITDA | $193M | XXX | $178M | XXX | XXX | XXX |
| EBITDA Margin | 17% | XXX | 16% | XXX | XXX | XXX |
| EBIT | $123M | XXX | $90.7M | XXX | XXX | XXX |
| EBIT Margin | 11% | XXX | 8% | XXX | XXX | XXX |
| Net Profit | $85.4M | XXX | $81.2M | XXX | XXX | XXX |
| Net Margin | 8% | XXX | 7% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $115M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Tecan Group's stock price is CHF 164 (or $197).
Tecan Group has current market cap of CHF 2.1B (or $2.5B), and EV of CHF 2.0B (or $2.4B).
See Tecan Group trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.4B | $2.5B | XXX | XXX | XXX | XXX | $8.28 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Tecan Group has market cap of $2.5B and EV of $2.4B.
Tecan Group's trades at 2.1x EV/Revenue multiple, and 13.5x EV/EBITDA.
Equity research analysts estimate Tecan Group's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Tecan Group has a P/E ratio of 29.3x.
See valuation multiples for Tecan Group and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2.5B | XXX | $2.5B | XXX | XXX | XXX |
| EV (current) | $2.4B | XXX | $2.4B | XXX | XXX | XXX |
| EV/Revenue | 2.1x | XXX | 2.1x | XXX | XXX | XXX |
| EV/EBITDA | 12.4x | XXX | 13.5x | XXX | XXX | XXX |
| EV/EBIT | 19.5x | XXX | 26.4x | XXX | XXX | XXX |
| EV/Gross Profit | 6.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | 29.3x | XXX | 30.8x | XXX | XXX | XXX |
| EV/FCF | 18.0x | XXX | 17.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialTecan Group's last 12 month revenue growth is 1%
Tecan Group's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.
Tecan Group's rule of 40 is 21% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Tecan Group's rule of X is 21% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Tecan Group and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 1% | XXX | 2% | XXX | XXX | XXX |
| EBITDA Margin | 17% | XXX | 16% | XXX | XXX | XXX |
| EBITDA Growth | 6% | XXX | -11% | XXX | XXX | XXX |
| Rule of 40 | 21% | XXX | 17% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 21% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 12% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 7% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 26% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Tecan Group acquired XXX companies to date.
Last acquisition by Tecan Group was XXXXXXXX, XXXXX XXXXX XXXXXX . Tecan Group acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Tecan Group founded? | Tecan Group was founded in 1980. |
| Where is Tecan Group headquartered? | Tecan Group is headquartered in Switzerland. |
| How many employees does Tecan Group have? | As of today, Tecan Group has 3.9K+ employees. |
| Is Tecan Group publicy listed? | Yes, Tecan Group is a public company listed on SWX. |
| What is the stock symbol of Tecan Group? | Tecan Group trades under TECN ticker. |
| When did Tecan Group go public? | Tecan Group went public in 2001. |
| Who are competitors of Tecan Group? | Similar companies to Tecan Group include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Tecan Group? | Tecan Group's current market cap is $2.5B |
| What is the current revenue of Tecan Group? | Tecan Group's last 12 months revenue is $1.1B. |
| What is the current revenue growth of Tecan Group? | Tecan Group revenue growth (NTM/LTM) is 1%. |
| What is the current EV/Revenue multiple of Tecan Group? | Current revenue multiple of Tecan Group is 2.1x. |
| Is Tecan Group profitable? | Yes, Tecan Group is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Tecan Group? | Tecan Group's last 12 months EBITDA is $193M. |
| What is Tecan Group's EBITDA margin? | Tecan Group's last 12 months EBITDA margin is 17%. |
| What is the current EV/EBITDA multiple of Tecan Group? | Current EBITDA multiple of Tecan Group is 12.4x. |
| What is the current FCF of Tecan Group? | Tecan Group's last 12 months FCF is $133M. |
| What is Tecan Group's FCF margin? | Tecan Group's last 12 months FCF margin is 12%. |
| What is the current EV/FCF multiple of Tecan Group? | Current FCF multiple of Tecan Group is 18.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
